Dashboard
Manage Tickers

ALLR Allarity Therapeutics, Inc.

Nasdaq allarity.com


$ 1.04 $ -0.04 (-3.7 %)    

Thursday, 20-Nov-2025 13:38:47 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 589.37 $ -22.30 (-3.65 %)
DIA $ 459.68 $ -6.97 (-1.49 %)
SPY $ 656.06 $ -16.84 (-2.5 %)
TLT $ 89.21 $ 0.22 (0.25 %)
GLD $ 375.26 $ 0.15 (0.04 %)
$ 1.07
$ 1.13
$ 1.04 x 210
$ 1.05 x 300
$ 1.03 - $ 1.14
$ 0.61 - $ 2.35
352,382
na
16.92M
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-15-2025 06-30-2025 10-Q
3 05-09-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-05-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 03-08-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-13-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 10-07-2022 06-30-2022 10-Q
15 05-27-2022 03-31-2022 10-Q
16 05-16-2022 09-30-2021 10-Q
17 05-16-2022 12-31-2021 10-K
18 11-23-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

allarity-therapeutics-q3-eps-019-beats-021-estimate
Allarity Therapeutics Q3 EPS $(0.19) Beats...
11/14/2025 14:11:21

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of...

ascendiant-capital-maintains-buy-on-allarity-therapeutics-raises-price-target-to-925
Ascendiant Capital Maintains Buy on Allari...
09/26/2025 09:55:13

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ: ALLR) with a Buy and raises the price target ...

reported-earlier-allarity-therapeutics-enters-into-a-securities-purchase-agreement--secures-25m
Reported Earlier: Allarity Therapeutics En...
09/23/2025 18:11:22

-SEC Filing

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
09/22/2025 17:06:11

allarity-therapeutics-highlights-presentation-of-phase-2-clinical-data-for-stenoparib2x-121-showing-median-overall-survival-now-surpassed-25-months
Allarity Therapeutics Highlights Presentat...
09/22/2025 12:11:25

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/27/2025 12:08:39

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/26/2025 17:06:55

crude-oil-down-2-us-durable-goods-orders-decline-in-july
Crude Oil Down 2%; US Durable Goods Orders...
08/26/2025 16:16:24

us-stocks-mixed-american-woodmark-posts-downbeat-sales
US Stocks Mixed; American Woodmark Posts D...
08/26/2025 13:55:28

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/26/2025 12:09:56

fda-grants-allarity-therapeutics-granted-fast-track-designation-for-stenoparib-for-advanced-ovarian-cancer-treatment
FDA Grants Allarity Therapeutics Granted F...
08/26/2025 12:04:02

stock-market-today-nasdaq-100-futures-slip-palo-alto-xp-allarity-earnings-in-focus-updated
Stock Market Today: Nasdaq 100 Futures Sli...
08/18/2025 12:51:50

U.S. stock futures slipped on Monday following Friday's mixed moves. Futures of major benchmark indices were lower.

palo-alto-networks-fabrinet-and-3-stocks-to-watch-heading-into-monday
Palo Alto Networks, Fabrinet And 3 Stocks ...
08/18/2025 07:15:21

allarity-therapeutics-q2-eps-015-beats-021-estimate
Allarity Therapeutics Q2 EPS $(0.15) Beats...
08/15/2025 20:32:59

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of...

this-mongodb-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday
This MongoDB Analyst Begins Coverage On A ...
07/28/2025 12:08:27

ascendiant-capital-initiates-coverage-on-allarity-therapeutics-with-buy-rating-announces-price-target-of-9
Ascendiant Capital Initiates Coverage On A...
07/28/2025 09:39:43

Ascendiant Capital analyst Edward Woo initiates coverage on Allarity Therapeutics (NASDAQ:ALLR) with a Buy rating and announ...

allarity-therapeutics-signs-licensing-and-laboratory-services-agreement-with-an-eu-based-biotechnology-company-to-supply-transcriptome-analysis-services
Allarity Therapeutics Signs Licensing And ...
07/15/2025 12:11:58

allarity-therapeutics-appoints-jeff-ervin-as-cfo-succeeds-alexander-epshinsky
Allarity Therapeutics Appoints Jeff Ervin ...
07/07/2025 12:08:10

allarity-therapeutics-patent-application-for-drp-companion-diagnostic-for-stenoparib-accepted-by-ip-australia
Allarity Therapeutics' Patent Application ...
06/30/2025 12:12:52

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutica...

allarity-therapeutics-doses-second-patient-in-phase-2-trial-of-stenoparib-for-advanced-ovarian-cancer
Allarity Therapeutics Doses Second Patient...
06/27/2025 12:10:03

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION